Philip L. Johnson is CFO & VP at Jazz Pharmaceuticals plc (JAZZ). They have made 1 open-market trade across 1 company since 2024, most recently 2026-06-30.
CIK 0002013156
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.4M since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JAZZ | 56,431 | $11.9M |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JAZZ | BUY | 2024-03-01 | 2024-03-05 | $119.65 | $1.4M | +0.0% | -4.7% | -12.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.